Kyverna Therapeutics (KYTX) Insider Trading & Ownership $4.12 +0.04 (+0.98%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Kyverna Therapeutics (NASDAQ:KYTX) Insider Buying and Selling ActivityNumber OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$9.90 MNumber OfInsiders Selling(Last 12 Months)0 Get KYTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Kyverna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KYTX Insider Buying and Selling by Quarter Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Kyverna Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/12/2024Northpond Ventures Iii Gp, LlcMajor ShareholderBuy450,000$22.00$9,900,000.00 (Data available from 1/1/2013 forward) KYTX Insider Trading Activity - Frequently Asked Questions Who is on Kyverna Therapeutics's Insider Roster? The list of insiders at Kyverna Therapeutics includes Northpond Ventures Iii Gp, Llc. Learn more on insiders at KYTX. Which Kyverna Therapeutics insiders have been buying company stock? The following insider purchased KYTX shares in the last 24 months: Northpond Ventures Iii Gp, Llc ($9,900,000.00). How much insider buying is happening at Kyverna Therapeutics? Insiders have purchased a total of 450,000 KYTX shares in the last 24 months for a total of $9,900,000.00 bought. Kyverna Therapeutics Key ExecutivesDr. Peter Maag Ph.D. (Age 57)CEO & Director Compensation: $709.99kMs. Karen Walker (Age 62)Chief Technology Officer Compensation: $561.64kDr. James Chung M.D. (Age 56)Ph.D., Chief Medical Officer Compensation: $645.62kDr. Tom Van Blarcom Ph.D.Senior VP & Head of ResearchMs. Portia SerameVice President of Human ResourcesDr. Dominic Borie M.D. (Age 61)Ph.D., President of Research & Development Mr. Devin MurraySenior Vice President of Partnerships & Alliances More Insider Trading Tools from MarketBeat Related Companies TRDA Insider Trades CRMD Insider Trades TECX Insider Trades PHAT Insider Trades ORIC Insider Trades ANAB Insider Trades STOK Insider Trades DNTH Insider Trades TRML Insider Trades IMNM Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:KYTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
